Modelling pharmaceutical price changes in Germany: a function of competition and regulation

References

• Augurzky , B . 2009 . Göhlmann, S., Greß, S. and Wasem, J. , Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach, Health Economics, 18, 421–36
   Google Scholar
• Bergman , MA and Rudholm , N . 2003 . The relative importance of actual and potential competition: empirical evidence from the pharmaceutical market . The Journal of Industrial Economics , 51 : 455 – 67 .
   Web of Science ®Google Scholar
• Bundesverband , BKK . 2005 . Arzneimittel Vertragspolitik August 2005 Essen
   Google Scholar
• Busse , R , Schreyögg , J and Henke , K-D . 2005 . Pharmaceutical regulation in Germany: improving efficiency and controlling expenditures . International Journal of Health Planning and Management , 20 : 329 – 49 .
   PubMed Web of Science ®Google Scholar
• Cline , R and Gupta , K . 2006 . Drug benefit decisions among older adults: a policy-capturing analysis . Medical Decision Making , 26 : 273 – 81 .
   PubMedGoogle Scholar
• Danzon , PM . 2001 . “ Reference pricing: theory and evidence ” . In Reference Pricing and Pharmaceutical Policy , Edited by: López-Casasnovas , G and Jönsson , B . 86 – 126 . Barcelona : Springer .
   Google Scholar
• Danzon , PM and Furukawa , M . 2003 . Prices and availability of pharmaceuticals: evidence from nine countries . Health Affairs , W3 : 521 – 36 .
   Google Scholar
• Frank , R and Salkever , D . 1997 . Generic entry and the pricing of pharmaceuticals . Journal of Economics and Management Strategy , 6 : 75 – 90 .
   Web of Science ®Google Scholar
• Furberg , C , Herrington , D and Psaty , B . 1999 . Are drugs within a class interchangable? . The Lancet , 354 : 1202 – 4 .
   PubMed Web of Science ®Google Scholar
• Garattini , L , Cornago , D and De Compadri , P . 2007 . Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis . Health Policy , 85 : 305 – 13 .
   PubMedGoogle Scholar
• Garattini , L and Tediosi , F . 2000 . A comparative analysis of generics markets in five European countries . Health Policy , 51 : 149 – 62 .
   PubMed Web of Science ®Google Scholar
• Giuliani , G , Selke , G and Garattini , L . 1998 . The German experience in reference pricing . Health Policy , 44 : 73 – 85 .
   PubMed Web of Science ®Google Scholar
• Grabowski , HG , Ridley , DB and Schulman , KA . 2007 . Entry and competition in generic biologics . Managerial and Decision Economics , 28 : 439 – 51 .
   Google Scholar
• Grabowski , HG and Vernon , J . 1996 . Longer patents for increased generic competition in the US . Pharmacoeconomics , 10 : 110 – 23 .
   PubMed Web of Science ®Google Scholar
• Greß , S , Niebuhr , D , May , U and Wasem , J . 2007 . Reform of prescription drug reimbursement and pricing in the German Social Health Insurance market . Pharmacoeconomics , 25 : 443 – 54 .
   PubMed Web of Science ®Google Scholar
• Hudson , J . 1992 . Pricing dynamics in the pharmaceutical industry . Applied Economics , 24 : 103 – 12 .
   Web of Science ®Google Scholar
• Jones , JCH , Potashnik , T and Zhang , A . 2001 . Patents, brand-generic competition and the pricing of ethical drugs in Canada: some empirical evidence from British Columbia . Applied Economics , 33 : 947 – 56 .
   Web of Science ®Google Scholar
• Kaló , Z , Muszbek , N , Bodrogi , J and Bidló , J . 2007 . Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence . Health Policy , 80 : 402 – 12 .
   PubMed Web of Science ®Google Scholar
• Kephart , G , Skedgel , C , Sketris , I , Grootendorst , P and Hoar , J . 2007 . Effect of copayments on drug use in the presence of annual payment limits . The American Journal of Managed Care , 13 : 328 – 34 .
   PubMedGoogle Scholar
• Kong , Y . 2004 . The price premium of generic to brand-names and pharmaceutical price index . Applied Economics , 36 : 731 – 37 .
   Web of Science ®Google Scholar
• López-Casasnovas , G and Puig-Junoy , J . 2001 . “ Review of the literature on reference pricing ” . In Reference Pricing and Pharmaceutical Policy , Edited by: López-Casasnovas , G and Jönsson , B . 1 – 41 . Barcelona : Springer .
   Google Scholar
• Lu , ZJ and Comanor , WS . 1998 . Strategic pricing of new pharmaceuticals . The Review of Economics and Statistics , 80 : 108 – 18 .
   Web of Science ®Google Scholar
• Magazzini , L , Pammolli , F and Riccaboni , M . 2004 . Dynamic competition in pharmaceuticals . The European Journal of Health Economics , 5 : 175 – 82 .
   PubMedGoogle Scholar
• Mrazek , MF and Mossialos , E . 2004 . “ Regulating pharmaceutical prices in the European Union ” . In Regulating Pharmaceuticals in Europe: Stricing for Efficiency, Equity and Quality , Edited by: Mossialos , E , Mrazek , MF and Walley , T . 114 – 29 . Cornwall : World Health Organization on behalf of the European Observatory on Health Care Systems and Policies .
   Google Scholar
• Pavcnik , N . 2002 . Do pharmaceutical prices respond to potential patient out-of-pocket expenses . RAND Journal of Economics , 33 : 469 – 87 .
   PubMed Web of Science ®Google Scholar
• Puig-Junoy , J . (2005a) The impact of generic reference pricing, interventions in the statin market, Universitat Pompeu Fabra, Department of Economics and Business, Research Centre for Economics and Health
   Google Scholar
• Puig-Junoy , J . 2005b . What is required to evaluate the impact of pharmaceutical reference pricing . Applied Health Economics and Health Policy , 4 : 87 – 98 .
   PubMedGoogle Scholar
• Reekie , W . 1998 . How competition lowers the costs of medicines . Pharmacoeconomics , 14 : 107 – 13 .
   PubMedGoogle Scholar
• Regan , TL . 2008 . Generic entry, price competition, and market segmentation in the prescription drug market . International Journal of Industrial Organization , 26 : 930 – 48 .
   Web of Science ®Google Scholar
• Reiffen , D and Ward , MR . 2005 . Generic drug industry dynamics . The Review of Economics and Statistics , 87 : 37 – 49 .
   Web of Science ®Google Scholar
• Rudholm , N . 2003 . Competition and substitutability in the Swedish pharmaceuticals market . Applied Economics , 35 : 1609 – 17 .
   Web of Science ®Google Scholar
• Schneeweiss , S , Schöffski , O and Selke , G . 1998 . What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? . Health Policy , 44 : 253 – 60 .
   PubMedGoogle Scholar
• Schreyögg , J and Busse , R . 2005 . Drug budgets and effects on physicians' prescription behaviour: new evidence from Germany . Journal of Pharmaceutical Finance, Economics and Policy , 14 : 77 – 95 .
   Google Scholar
• Searles , A , Jefferys , S , Doran , E and Henry , D . 2007 . Reference pricing, generic drugs and proposed changes to the pharmaceutical benefits scheme . The Medical Journal of Australia , 8 : 4 – 36 .
   Google Scholar
• Snijders , T and Bosker , R . 1999 . Multilevel Analysis, an Introduction to Basic and Advanced Multilevel Modeling , London : SAGE Publications .
   Google Scholar
• Stargardt , T , Schreyögg , J and Busse , R . 2005 . Arzneimittelfestbeträge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen . Das Gesundheitswesen , 67 : 468 – 77 .
   PubMedGoogle Scholar
• Suh , D , Manning , W , Schondelmeyer , S and Hadsall , R . 2000 . Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industrie . Health Services Research , 35 : 529 – 47 .
   PubMed Web of Science ®Google Scholar
• Verbeke , G and Molenberghs , G . 2000 . Linear Mixed Models for Longitudinal Data , New York : Springer .
   Google Scholar